Clinical Trials Browser

Interventional × duvelisib × 30 days × Clear all

NCT04652960 2026-04-13

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

Phase 1 Active not recruiting

Mycosis Fungoides, Sezary Syndrome

NCT05010005 2026-04-09

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Phase 1 Recruiting

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Leukemia, Large Granular Lymphocytic

NCT07001384 2026-04-08

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Phase 1 Recruiting

Lymphoma, Large-Cell, Anaplastic

NCT06522737 2026-04-06

TERZO

Phase 3 Recruiting

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral

NCT04803201 2026-04-02

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Phase 2 Suspended

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT03534323 2026-03-23

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

Phase 1/2 Active not recruiting

55 enrolled 14 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell